Navigation Links
Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
Date:6/20/2013

ty of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are e
'/>"/>

SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
2. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
3. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
4. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
5. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
6. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
7. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
8. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
9. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
10. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
11. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... Dec. 14, 2010 Samplify Systems, Inc., a ... the ultrasound market, is pleased to announce that ... has won Electronic Design Magazine,s Best ... category.  Details of Samplify,s AutoFocus™ beamforming technology currently ...
... 14, 2010 Pacira Pharmaceuticals, Inc. ... the New Drug Application (NDA) for EXPAREL™, a long-acting ... filing by the U.S. Food and Drug Administration (FDA). ... the initial indication of postsurgical analgesia by local administration. ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2
(Date:8/31/2015)... ... August 31, 2015 , ... GenHart Software, LLC, a rising player in ... small businesses operate as efficiently and cost effectively as possible, with a belief that ... their first year of operation – and the Charleston business community is taking notice. ...
(Date:8/30/2015)... , ... August 31, 2015 , ... Avid collector Andrew ... the Doors Shrine Auditorium concert posters. This hand colored artwork is one of the ... in Los Angles. Hawley states, "When the doors played the Shrine, the band ...
(Date:8/30/2015)... DE (PRWEB) , ... August 31, 2015 , ... ... exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & 6th ... and organizations together, the AHCA/NCAL convention brings industry professionals from all over the ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... across platforms and devices, today announced it is a Silver Sponsor of the ... at Sky City Convention Centre in Auckland, NZ. Throughout the event, AvePoint will ...
(Date:8/30/2015)... ... ... Natural Rest contains a unique mixture of vitamins and herbs that are ... to improve mood disorders and anxiety. Like all other Creative Medical Health products, Natural ... regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one of ...
Breaking Medicine News(10 mins):Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2
... woman who comes to a health care centre does increase ... partners, a new study confirms. The study, led by ... at St. Michael,s Hospital, represents a major reversal of thinking ... or intimate partner violence. Until now, the research and ...
... around 2 billion dollars a year on remediation at ... used for groundwater monitoring. Yet according to Rolf Halden, ... information gathered is often of limited value. Under ... Department of Defense, Halden, assistant director at the Institute,s ...
... -- The sooner rehabilitation begins after knee replacement, the ... In the study, published March 7 in the ... than 150 patients who began rehabilitation within 24 hours ... of patients who began rehabilitation 48 to 72 hours ...
... , FRIDAY, March 4 (HealthDay News) -- In what experts ... have for the first time turned human embryonic stem cells ... of brain cell that,s lost to Alzheimer,s disease. The ... cholinergic" (BFC) neurons, is key to the progression of Alzheimer,s. ...
... Walter and Eliza Hall Institute have identified the key ... response. The finding could have wide-ranging repercussions for ... and change how the efficacy of newly developed drugs ... Erika Cretney, Dr Axel Kallies and Dr Stephen Nutt ...
... Sledding is the most common cause of injury among winter ... list of the top five injury-causing winter activities. "More ... States due to sledding. More than 30 percent are head ... specialist at Gottlieb Memorial Hospital in Melrose Park, Ill., part ...
Cached Medicine News:Health News:Universal screening programs can uncover abuse, study finds 2Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 3Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 4Health News:Newly identified cell population key to immune response 2
Cold light source single outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Medicine Products: